Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study.

Area of Science:

• Neuroscience
• Developmental Pediatrics
• Nutritional Science

Background:

• Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors.
• Sulforaphane (SFN), a compound found in cruciferous vegetables, has shown potential in preclinical studies for alleviating autistic behaviors.
• Existing research warrants further investigation into SFN's efficacy in pediatric ASD populations.

Purpose of the Study:

• To investigate the therapeutic effect of sulforaphane (SFN) on behavioral outcomes in children diagnosed with autism spectrum disorder (ASD).
• To evaluate changes in social interaction, communication, and aberrant behaviors using standardized assessments.
• To determine if SFN supplementation offers a clinically significant benefit in a pediatric cohort aged 3-7 years.

Main Methods:

• A prospective, double-blind, placebo-controlled study was conducted over 36 weeks.
• Participants included 40 children aged 3-7 years with ASD; 28 completed the study.
• Assessments included the Autism Diagnostic Observation Schedule-2 (ADOS-2), Social Responsiveness Scale-2 (SRS-2), and Aberrant Behaviour Checklist (ABC).

Main Results:

• While mean scores on the ABC and SRS-2 showed improvement in both SFN and placebo groups, these changes did not reach statistical significance.
• No significant differences were observed between the SFN and placebo groups in ADOS-2 subscale scores.
• The study found no statistically significant clinical improvement in the evaluated behavioral outcome measures for children treated with SFN.

Conclusions:

• Sulforaphane (SFN) supplementation did not demonstrate significant clinical efficacy in improving behavioral outcomes for children aged 3-7 years with autism spectrum disorder (ASD).
• Further research may be needed to explore alternative dosages, treatment durations, or specific ASD subgroups.
• The findings suggest that SFN, at the tested dosage and duration, is not an effective intervention for the core symptoms of ASD in this age group.